Pipeline

Ko te R&D a Sorrento e arotahi ana ki te akiaki i nga mahi hou i roto i te COVID-19, te maimoatanga mate pukupuku, te whakahaere mamae katoa me nga mate autoimmune.

Papatono Matua Whakaatu Tuhinga o mua Wahanga I Wahanga II Wāhanga III/Pivotal Whakaaetanga FDA
Kaupapa COVID-19  

COVISTIX™ (tātari) Whakamātautau Antigen Tere

*

Whakaaetanga Whakamahi ohorere (EUA) i Mexico (COFEPRIS), Brazil (ANVISA), me te tohu CE i Uropi

COVIMARK™ (tātari) Whakamātautau Antigen Tere

*

Tono i tukuna i te US me Kanata mo te Whakaaetanga Whakamahi ohorere (EUA)

VIREX (tātari) I te Whare Taonga

60.2%*

EUA Enabling Studies in Q3 2022

COVISHIELD™ (maimoatanga) Te whakakore i te Antibody (IV) i roto i nga Turoro me nga Turoro

20%*

FUJOVEE™ (Abivertinib) COVID-19 kino i roto i nga turoro ICU

82%*

Ko te Whakamātautau Pivotal e tatari ana ki te Whakaaetanga FDA

OQORY™ (COVI-MSC) ARDS na te COVID-19 i roto i nga turoro ICU

82%*

Whakamātautau Pivotal i Brazil

Mpro Kaitautoko (pire waha) Anati-mate

40%*

Omicron mRNA Vaccine kano

20%*

Papatono Matua Whakaatu Tuhinga o mua Wahanga I Wahanga II Wāhanga III/Pivotal Whakaaetanga FDA
immunotherapy  

FUJOVEE™ (Abivertinib) NSCLC

82%*

FUJOVEE™ (Abivertinib) B Lymphomas Pūtau

60.2%*

FUJOVEE™ (Abivertinib) Patohi

20%*

FUJOVEE™ (Abivertinib) Lupus

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

*Ma te mahi tahi me Lee's Pharm i Haina

PD-L1 (STI-3031)** He mate pukupuku

82%*

**I US me te mahi tahi me ImmuneOncia i Korea

CD47 Nga pukupuku totoka

40%*

CD38 DAR-T Te maha o te taurua

40%*

CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, me te esophageal

40%*

Seprehvec™ huaketo oncolytic Nga pukupuku totoka; Nga pukupuku CNS

40%*

BCMA ADC Nga Pumo Wai

20%*

Bevacizumab-ADNAB™ Te mate pukupuku Endometrial

40%*

I roto i te mahi tahi me Mayo Clinic

Bevacizumab-ADNAB™ Ko te mate pukupuku ovarian

40%*

I roto i te mahi tahi me Mayo Clinic

Rituximab-ADNAB™ Lymphomas pūtau-B

40%*

I roto i te mahi tahi me Mayo Clinic

Sofusa® anti-PD-1 Putau T-Cell Lymphoma (CTCL), Melanoma

40%*

Papatono Matua Whakaatu Tuhinga o mua Wahanga I Wahanga II Wāhanga III/Pivotal Whakaaetanga FDA
Pain  

ZTlido® 1.8 orau
Neuralgia Postherpetic - PHN

99.8%*

Gloperba®
Te maimoatanga o te kauti (waha)

99.8%*

SEMDEXA (SP-102) Te mamae o te Lumbar Radicular / Sciatica

82%*

SP-103 (Lidocaine Topical System 5.4%) Te mamae o muri

60.2%*

SP-104 (Naltrexone Te Putanga Iti Te Putanga) Fibromyalgia

20%*

RTX (resiniferatoxin)
Werohia epidural
Te mamae i roto i te mate pukupuku matatau

60.3%*

Te ingoa pani

RTX (resiniferatoxin)
Te ara-a-roto
Te mamae o te turi ki te kino OA

60.2%*

Papatono Matua Whakaatu Tuhinga o mua Wahanga I Wahanga II Wāhanga III/Pivotal Whakaaetanga FDA
Te Tukunga Rongoa Lymphatic  

Sofusa® anti-TNF Aunoa (RA)

40%*

Sofusa® anti-PD-1 Putau T-Cell Lymphoma (CTCL), Melanoma

40%*

Sofusa® anti-CTLA-4 Melanoma

40%*

I roto i te mahi tahi me Mayo Clinic
Kaupapa COVID-19
Papatono Matua (tohu) Waahi
COVISTIX™ (tātari) FDA EUA
COVIMARK™ (tātari) FDA EUA
VIREX (tātari) PH III
COVISHIELD™ (maimoatanga) PH I
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Mpro Inhibitor (pire waha) Ph II
Omicron mRNA Vaccine Tuhinga o mua
immunotherapy
Papatono Matua (tohu) Waahi
FUJOVEE™ (Abivertinib) Ph III
FUJOVEE™ (Abivertinib) Ph II
FUJOVEE™ (Abivertinib) Tuhinga o mua
FUJOVEE™ (Abivertinib) Tuhinga o mua
FUJOVEE™ (Abivertinib) Tuhinga o mua
FUJOVEE™ (Abivertinib) Tuhinga o mua
PD-L1 (Socazolimab)* Ph III
PD-L1 (STI-3031)** Ph III
CD47 (Tumu totoka) Ph I
CD38 DAR-T (Maamaa Maha) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, me te esophageal) Ph I
Seprehvec™ huaketo oncolytic (Tumor Too; Tumor CNS) PH I
BCMA ADC (Tumo Wai) Tuhinga o mua
Bevacizumab-ADNAB™ (Te mate pukupuku Endometrial) Ph I
Bevacizumab-ADNAB™ (Te mate pukupuku ovarian) Ph I
Rituximab-ADNAB™ (Rumoma-a-B) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
Pain
Papatono Matua (tohu) Waahi
ZTlido® 1.8 orau (Postherpetic Neuralgia - PHN) Whakaaetanga FDA
Gloperba® 1.8 orau Te maimoatanga o te kauti (waha) Whakaaetanga FDA
SEMDEXA (SP-102) Ph III
SP-103 (Lidocaine Topical System 5.4%) Ph II
SP-104 (Naltrexone Te Putanga Iti Te Putanga) Tuhinga o mua
RTX (resiniferatoxin) Werohia epidural Ph II
RTX (resiniferatoxin) Te ara-a-roto Ph II
Tukunga Lymphatic
Papatono Matua (tohu) Wahanga II
Sofusa® anti-TNF (Autoimmune RA) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
Sofusa® anti-CTLA-4 (Melanoma) Ph I